연세대학교 · Medicine
홍명기 교수의 연구실은 관상동맥 질환에서 stent 치료의 장기적 결과와 병변 특성에 대한 심층적인 이해를 목표로 합니다. 주로 IVUS(血管내 초음파)를 활용한 레이저 스테인팅 모니터링(LSM), 스텐트의 병변 반응 및 재관류 여부에 영향을 미치는 요인, 그리고 약물이식 스텐트의 효과성과 안정성에 대한 연구를 수행하고 있습니다. 특히 급성 심근경색 환자에서의 병변 파손 패atters와 염증 반응의 연관성, 스텐트 길이 및 면적 등 구체적 생체 영상 지표가 치료 결과에 미치는 영향을 규명하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
LSM occurs in 12% of cases after DES implantation. The predictors of LSM are total stent length, primary stenting in acute myocardial infarction, and chronic total occlusion lesions. LSM after DES implantation was not associated with any major adverse cardiac events during a subsequent 10-month (mean) follow-up.
Three-vessel IVUS imaging showed that culprit lesion plaque rupture, secondary remote plaque ruptures, and multiple plaque ruptures were all more common in AMI patients than SAP patients. In AMI patients, plaque rupture was associated with a high CRP level, whereas in SAP patients, plaque rupture was more common in those with diabetes.
Independent predictors of angiographic restenosis after SES implantation were post-procedural final minimum stent area by IVUS and IVUS-measured stent length. The angiographic restenosis rate was highest in lesions with stent area<5.5 mm2 and stent length>40 mm.
Paclitaxel-coated stents are effective in reducing in-stent neointimal tissue proliferation in humans. They are not associated with edge restenosis or significant late malapposition.
LSM occurs in approximately 5% after BMS implantation. The predictors of LSM are primary stenting in acute myocardial infarction and DCA before stenting. Compared with complete stent apposition at follow-up, LSM after BMS implantation is not associated with any major adverse cardiac events during a mean 3-year follow-up after detection of LSM.
